Company: INDP
Filing Date: 2025-11-12
Form Type: 10-Q
Source: 0001493152-25-021759
Chunk: 15

Company: Indaptus Therapeutics, Inc.
Filing Date: 2025-11-12
Form: 10-Q
Item: Part I, Item 1
Chunk 15
---
.

 SCHEDULE
OF WEIGHTED AVERAGE INPUTS USED TO MEASURE VALUE OF OPTIONS GRANTED 

    2025

    Exercise
    price
     
    $
    9.24

    Expected
    term (in years)

    5.5

    Volatility

    128.4
    %
  
    Risk
    free rate

    4.1
    %
  
    Dividend
    yield

    0
    %

    F-9

The
following table presents the exercise price of outstanding stock options as of September 30, 2025:

 SCHEDULE
OF EXERCISE PRICE OF OUTSTANDING STOCK OPTIONS 

    Exercise price 
    Options  outstanding 

    $0.01 - $80.00 
     55,777 

    $0.01 - $80.00 
     55,777 
  
    $80.01 or higher 
     48,619 
  
    Total 
     104,396 

NOTE
6: CAPITALIZATION

    a.
    As
    of September 30, 2025 and December 31, 2024, the Company had 200,000,000 shares of common stock authorized and 1,641,920 and 428,799
    shares issued and outstanding, respectively. As of September 30, 2025 and December 31, 2024, the Company had 5,000,000 shares of
    preferred stock authorized. There were no shares of preferred stock issued or outstanding as of September 30, 2025 and December 31,
    2024. As of September 30, 2025 and December 31, 2024, there were warrants outstanding to purchase an aggregate of 1,780,159 and 238,423
    shares of common stock, respectively. As of September 30, 2025, these warrants were exercisable at a weighted average price of $29.14
    and their weighted average remaining contractual term was 4.5 years. As of September 30, 2025, there were pre-funded warrants outstanding
    to purchase an aggregate of 175,404 shares of common stock exercisable at $0.01 with no expiration date.

    b.
    On
    January 16, 2025, the Company completed a private placement offering pursuant to which the Company sold and issued to certain investors